ICH Q11: Development and Manufacture of Drug Substances
ICH Q11 provides guidance on the development and manufacture of drug substances (APIs), covering both traditional and enhanced (QbD) approaches to process development, starting material selection and justification, manufacturing process description, control strategy, and the information expected in CTD Sections 3.2.S.2.2 through 3.2.S.2.6.
Key Takeaways
Key Takeaways
- ICH Q11 extends QbD principles from drug product (Q8) to drug substance manufacturing, covering both chemical and biotechnological entities in CTD Section 3.2.S
- Starting material selection is a regulatory flashpoint; Q11 Q&A guidance provides principles for justification, and agencies routinely challenge starting materials too close to the API
- Impurity fate and purge analysis enables science-based control strategies that reduce unnecessary testing while maintaining safety assurance
- Both traditional and enhanced (QbD) development approaches are acceptable; the enhanced approach enables design spaces and greater post-approval flexibility
- ICH Q11, titled "Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities)," extends the QbD principles of ICH Q8 to drug substance (API) manufacturing. Adopted at ICH Step 4 in November 2012, Q11 addresses a gap in the ICH quality guidelines: while Q8 covered drug product development (Module 3.2.P.2), there was no equivalent guidance for the drug substance development sections (3.2.S.2) of the CTD.
- Starting material selection, process description, impurity control, and the level of process understanding demonstrated in the filing are areas where regulatory agencies have historically applied inconsistent expectations. Q11 harmonizes these expectations across FDA, EMA, PMDA, and other ICH regions.
- In this guide, you'll learn:
- Traditional and enhanced approaches to drug substance process development per ICH Q11
- Starting material selection criteria and the principles for regulatory justification
- How to describe the manufacturing process in CTD Section 3.2.S.2.2
- Impurity fate and purge concepts for building science-based control strategies
- Control strategy development linking process understanding to specifications
- ---
What Is ICH Q11? Scope and Applicability
ICH Q11 applies to the drug substance (active pharmaceutical ingredient, API) used in pharmaceutical products for human use. It covers both chemically synthesized drug substances and biotechnological/biological drug substances, though the emphasis and specific guidance differs for each.
Scope
| Applies To | CTD Section | Content Guided |
|---|---|---|
| Drug substance development | 3.2.S.2.2 | Description of manufacturing process development |
| Manufacturing process description | 3.2.S.2.2 | Process flow, unit operations, controls |
| Control of materials | 3.2.S.2.3 | Starting materials, reagents, solvents, intermediates |
| Controls of critical steps and intermediates | 3.2.S.2.4 | In-process controls, intermediate specifications |
| Process validation | 3.2.S.2.5 | Validation approach and summary |
| Manufacturing process development | 3.2.S.2.6 | Development studies, process understanding |
What Q11 Does Not Cover
- Drug product development (covered by ICH Q8)
- Excipients (covered by regional guidance and ICH Q8)
- Drug substance specifications (covered by ICH Q6A/Q6B)
- Impurity identification and qualification (covered by ICH Q3A)
- Stability (covered by ICH Q1A/Q1B/Q5C)
Traditional vs. Enhanced Approaches
ICH Q11 Section 3 recognizes two development approaches, consistent with the ICH Q8 framework. The distinction centers on the depth of process understanding and the resulting regulatory flexibility.
Traditional Approach
The traditional approach relies on defined process parameters and fixed operating conditions established through manufacturing experience and limited optimization studies.
| Characteristic | Traditional Approach |
|---|---|
| Process development basis | Empirical; reaction conditions optimized sequentially |
| Process description | Fixed parameters with defined ranges |
| Control strategy | End-product testing as primary quality assurance |
| Specifications | Based on batch history and pharmacopeial standards |
| Regulatory flexibility | Limited; changes require prior approval supplements |
| Filing content in S.2.6 | Summary of development history |
Enhanced Approach
The enhanced approach uses systematic scientific methods to gain deeper process understanding, enabling design spaces, risk-based control, and greater regulatory flexibility.
| Characteristic | Enhanced Approach |
|---|---|
| Process development basis | Systematic; DoE, mechanistic models, PAT |
| Process description | Design space with demonstrated parameter interactions |
| Control strategy | Process understanding-based controls, reduced end-product testing |
| Specifications | Clinically relevant, justified by process capability |
| Regulatory flexibility | Movement within design space without prior approval |
| Filing content in S.2.6 | Detailed development studies, risk assessments, design space justification |
“Practical Reality: Most drug substance filings use a hybrid approach. Certain steps may be developed using QbD/enhanced methods (typically critical synthetic transformations or purification steps), while others use traditional fixed-parameter approaches (simple unit operations, well-understood chemistry).
Manufacturing Process Description (Section 3.2.S.2.2)
ICH Q11 Section 5 provides guidance on what should be included in the manufacturing process description. This section of the CTD must provide enough detail for the regulatory assessor to understand the process, evaluate the control strategy, and assess the quality of the drug substance produced.
Required Content
| Element | Description | Level of Detail |
|---|---|---|
| Process flow diagram | Sequential unit operations from starting materials to drug substance | All steps, including purification, isolation, and drying |
| Unit operation descriptions | Chemical reactions, physical processes, purification methods | Reaction conditions, reagents, solvents, catalysts |
| Process parameters | Operating conditions for each step | Ranges or design spaces with justification |
| In-process controls | Tests performed during manufacturing | Acceptance criteria, sampling points |
| Process intermediates | Defined intermediates isolated during synthesis | Specifications for isolated intermediates |
| Equipment | Types of equipment used (not specific models) | Generic descriptions (reactor, filter, dryer) |
| Yield ranges | Expected yields for each step and overall | Based on process validation/experience |
Level of Detail Expected
ICH Q11 Section 5.1 distinguishes between the level of detail required for different parts of the process:
- Steps after the last starting material: Full detail of reaction conditions, parameters, and controls
- Steps before the starting material: Generally not required in the filing, though the applicant must have this information available
- Critical steps: Identified with enhanced controls and justification
Starting Material Selection and Justification
Starting material selection is one of the most consequential decisions in a drug substance filing. ICH Q11 Section 6 provides principles for selecting and justifying starting materials, supplemented by the ICH Q11 Q&A document (Step 4, November 2017), which provides additional specificity.
Definition
ICH Q11 Section 4.1 defines a starting material as "a material used in the synthesis of the drug substance that is incorporated as a significant structural fragment into the structure of the drug substance."
Selection Principles
ICH Q11 Section 6.1 states that starting material selection should be based on considerations including:
| Principle | Description | Regulatory Concern |
|---|---|---|
| Significant structural fragment | Starting material contributes a significant portion of the drug substance molecular structure | Commercially available intermediates that are one step from the drug substance are rarely acceptable as starting materials |
| Multiple chemical transformations | Multiple synthetic steps should occur after the starting material to purge impurities | Fewer steps = less opportunity for impurity removal |
| Commercial availability and sourcing | Starting material should be commercially available or well-defined | Proprietary intermediates from a single source may raise supply chain concerns |
| Impurity profile impact | Impurities in the starting material must be controlled to ensure drug substance quality | Starting material impurity specifications must be justified |
| Regulatory precedent | Consistency with prior regulatory acceptances | Novel starting material choices may invite additional scrutiny |
The Q11 Q&A Document (2015)
The ICH Q11 Questions and Answers document (adopted at Step 4 in November 2017) provides critical supplemental guidance on starting material justification. It introduces six specific principles:
- The proposed starting material should be a well-defined substance that can be characterized and tested to adequate quality standards.
- General starting material principles apply regardless of the source. Whether commercially purchased or manufactured in-house, the same justification criteria apply.
- Consideration of impurity carry-through. The number of purification steps between the starting material and the drug substance should be sufficient to purge starting material impurities to acceptable levels.
- Complexity of manufacturing steps. Multiple chemical transformations after the starting material provide confidence that the process adequately controls quality.
- Regulatory assessors evaluate the totality of the proposed starting material. This includes its structure, commercial availability, specifications, and the overall synthetic route.
- Redefinition of starting materials may be requested if the regulatory agency determines that the proposed starting material is too close to the drug substance or does not meet the principles above.
Starting Material Specification Content
| Specification Element | Requirement | Purpose |
|---|---|---|
| Description | Physical appearance, form | Identity confirmation |
| Identification | IR, NMR, or other specific tests | Confirm correct material |
| Assay | Purity by appropriate method | Ensure adequate purity |
| Impurities | Individual and total impurity limits | Control impurity carry-through |
| Residual solvents | Per ICH Q3C if applicable | Safety |
| Physical properties | Particle size, polymorphic form if critical | Process performance |
“Common Regulatory Issue: FDA and EMA frequently request redefinition of starting materials when the proposed starting material is one or two simple transformations from the drug substance. The Q11 Q&A document specifically addresses this: "A one-step synthesis from a proposed starting material to the drug substance, in the absence of any other mitigating factors, would not normally be considered acceptable."
Impurity Fate and Purge
ICH Q11 Section 7 introduces the concept of evaluating the fate and purge of impurities throughout the manufacturing process. This science-based approach allows applicants to demonstrate that process steps inherently remove impurities, potentially reducing the need for testing at every intermediate stage.
The Purge Factor Concept
A purge factor quantifies how effectively a process step removes a specific impurity. Purge factors are determined by considering:
| Factor | Description | Assessment Approach |
|---|---|---|
| Reactivity | Will the impurity react in subsequent steps? | Chemical knowledge, reaction mechanisms |
| Solubility | Will the impurity be removed by crystallization or extraction? | Solubility data, partition coefficients |
| Volatility | Will the impurity be removed by distillation or drying? | Boiling points, vapor pressures |
| Physical removal | Will filtration, washing, or chromatography remove the impurity? | Process conditions, distribution data |
Calculating Purge Factors
Individual purge factors for each mechanism at each step are combined:
Purge factor scoring (semi-quantitative, per Teasdale et al., Org. Process Res. Dev. 2013):
| Score | Purge Expected | Purge Factor |
|---|---|---|
| 1 | No purge expected | 1 (no reduction) |
| 3 | Moderate purge likely | ~10x reduction |
| 10 | High purge expected | ~100x reduction |
| 100 | Very high purge expected | ~1000x reduction |
Application to Control Strategy
Impurity fate and purge analysis supports control strategy decisions:
| Scenario | Control Strategy Decision |
|---|---|
| High overall purge factor (>1000) for a starting material impurity | May not need routine testing in drug substance if starting material specification controls the impurity |
| Low purge factor for a process impurity | Need in-process control or drug substance specification test |
| Genotoxic impurity with moderate purge | Need validated analytical method and testing; purge data supports but does not replace testing per ICH M7 |
| Impurity with no purge mechanism | Must be controlled at point of introduction and in drug substance specification |
“Connection to ICH M7: For mutagenic impurities, purge factor analysis per ICH Q11 is explicitly referenced in ICH M7 (Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk) as a tool for establishing control strategies. However, ICH M7 requires that purge-based control be supported by experimental data, not just theoretical assessment.
Control Strategy for Drug Substances
ICH Q11 Section 8 describes how the control strategy integrates process understanding, impurity knowledge, and testing requirements to ensure drug substance quality.
Components of the Drug Substance Control Strategy
| Control Element | Traditional Approach | Enhanced Approach |
|---|---|---|
| Starting material specifications | Based on batch data and pharmacopeial standards | Risk-based, considering impurity fate and purge |
| In-process controls | Fixed tests at predefined steps | Risk-based, focused on critical steps; PAT where beneficial |
| Intermediate specifications | May include full testing of each intermediate | Testing focused on quality-critical intermediates; process understanding justifies reduced testing |
| Drug substance specification | Comprehensive, testing-heavy | Justified by process capability and understanding; may reduce routine testing for well-controlled attributes |
| Process parameters | Fixed ranges from batch experience | Design spaces for critical steps; proven acceptable ranges for others |
| Reprocessing/reworking | Defined procedures with specifications | Risk-based assessment; some reprocessing within design space |
Building the Control Strategy
The control strategy development follows this logic:
- Identify CQAs for the drug substance (purity, impurity profile, polymorphic form, particle size, residual solvents, etc.)
- Link CQAs to process parameters through development studies (DoE, mechanistic understanding)
- Evaluate impurity fate and purge to determine where impurity control is most effective
- Define critical process parameters and their acceptable ranges or design spaces
- Establish specifications for starting materials, intermediates, and drug substance based on process capability and clinical requirements
- Define in-process controls at critical steps where real-time process adjustment is needed
- Validate the control strategy through process validation studies (ICH Q11 Section 9)
Drug Substance Specification Justification
ICH Q11, in conjunction with ICH Q6A (Specifications for New Drug Substances and Products: Chemical Substances), requires that drug substance specifications be justified based on:
| Basis | Source |
|---|---|
| Safety qualification | ICH Q3A (impurity qualification thresholds) |
| Clinical experience | Batch data from clinical trial material |
| Process capability | Process validation and commercial batch data |
| Stability data | ICH Q1A stability studies |
| Pharmacopeial standards | Relevant monograph requirements |
| Regulatory precedent | Agency expectations for similar compounds |
Process Validation Linkage
ICH Q11 Section 9 addresses process validation for drug substances. The guidance aligns with the lifecycle approach to process validation promoted by FDA (2011 Process Validation guidance) and EU GMP Annex 15.
Validation Approach
| Development Approach | Validation Strategy | Key Consideration |
|---|---|---|
| Traditional | Prospective validation (3+ batches at commercial scale) | Must demonstrate reproducibility of fixed process |
| Enhanced | Continuous process verification may be appropriate | Design space verification at commercial scale; ongoing monitoring |
| Hybrid | Traditional validation for non-design-space steps; enhanced verification for design space steps | Most common approach in practice |
Process Validation Documentation in CTD
| CTD Section | Content |
|---|---|
| 3.2.S.2.5 | Process validation and/or evaluation summary |
| 3.2.S.2.2 | Process description (cross-reference to validation) |
| 3.2.S.4.4 | Batch analyses (data from validation batches) |
Biotechnological/Biological Drug Substances
ICH Q11 Section 11 provides specific guidance for biotechnological/biological drug substances, recognizing their unique manufacturing characteristics.
Key Differences from Chemical Entities
| Aspect | Chemical Drug Substance | Biotechnological Drug Substance |
|---|---|---|
| Starting material | Defined chemical starting material | Cell bank (MCB, WCB) |
| Process characterization | Chemical reactions with defined mechanisms | Biological processes with inherent variability |
| Impurity profile | Well-defined chemical impurities | Process-related (HCP, DNA, Protein A) and product-related (aggregates, charge variants) |
| Analytical characterization | Full structural elucidation possible | Limited by molecular complexity; product is defined by the process |
| Control strategy | Can be primarily testing-based | Process control is essential; product heterogeneity expected |
| Process changes | Impact can be predicted from chemistry | Impact requires comparability assessment (ICH Q5E) |
Cell Bank and Upstream Process
For biotechnological drug substances, Q11 Section 11 guidance covers:
| Element | Requirement |
|---|---|
| Cell bank characterization | MCB/WCB characterization per ICH Q5A (viral safety), Q5B (genetic stability), Q5D (cell substrates) |
| Cell culture process | Description of culture conditions, media composition, process parameters |
| Harvest and recovery | Cell removal, initial purification steps |
| Process-related impurities | HCP, DNA, endotoxin, Protein A (if used), cell culture media components |
| Product-related impurities | Aggregates, fragments, charge variants, glycosylation variants |
Common Regulatory Deficiencies in Q11 Filings
Based on published FDA and EMA review patterns for drug substance sections:
| Deficiency | CTD Section | How to Avoid |
|---|---|---|
| Starting material too close to drug substance | 3.2.S.2.3 | Apply Q11 Q&A principles; ensure multiple chemical transformations after starting material |
| Insufficient starting material specifications | 3.2.S.2.3 | Include identity, assay, impurities, residual solvents; justify limits |
| Missing impurity fate and purge data | 3.2.S.2.6 | Provide fate assessment for all specified impurities and mutagenic impurities |
| Inadequate process description | 3.2.S.2.2 | Include all unit operations, parameters, in-process controls; provide process flow diagram |
| Control strategy not justified | 3.2.S.2.4 | Link controls to CQAs through development data; explain why each control is placed where it is |
| Genotoxic impurity control not addressed | 3.2.S.2.6 | Evaluate per ICH M7; provide purge data or validated testing for relevant GTIs |
| Missing development rationale | 3.2.S.2.6 | Explain why the chosen process was selected; include optimization studies |
| Batch-to-batch variability not characterized | 3.2.S.4.4 | Provide batch data from at least 3 (preferably 6+) batches at commercial scale |
References
ICH Q11 principles apply to all drug substances, including those used in generic (ANDA) products. However, the level of development information required may differ. For ANDAs, FDA expects the drug substance section to contain sufficient information to evaluate the manufacturing process, starting materials, and control strategy, even if less development data is available compared to innovator filings.